Phase 1/2 clinical trial (NCT05384626) will evaluate dose-limiting toxicities, dosage, and ORR in ALK-positive advanced/metastatic NSCLC or other solid tumors (Inc, 2022). This evidence concerns the gene ALK and non-small cell lung carcinoma.